IFNB1 (118-132) Human – Immunology – Antigens/Epitotes/Pools/Librairies

Recombinant human interferon-β (IFNB) is a therapeutic for certain stages of multiple sclerosis (MS). However, a significant portion of patients develop neutralising antibodies within 2 years and prevent clinical efficacy of the treatment, this was correlated to a specific rise in IgG. Sequencing of IFNB1 revealed a CD4+ T cell epitope residues (118-132) that contains critical T cell activation residues. The identification of this sequences can now allow it to be manipulated to hopefully provide new interferon treatments that reduces the capacity for induction of neutralising antibodies in MS patients. The IFNB1 (118-132) epitope can be used for immunological investigations such as T cell activation, antibody recognition via immunoassays and immunohistochemistry. This may provide further insights into certain haplotypes correlating to IFNB responses in MS treatment.